Terutroban
Terutroban
Terutroban (pronounced: te-ru-tro-ban) is a thromboxane receptor antagonist that was under development for the secondary prevention of ischemic stroke and other related cardiovascular diseases.
Etymology
The name "Terutroban" is derived from its chemical structure, which is a derivative of the pyrimidinetrione class of compounds.
Pharmacology
Terutroban acts by selectively blocking the thromboxane A2 receptor, thereby inhibiting platelet aggregation and vasoconstriction. This mechanism of action is similar to that of aspirin, but Terutroban is more selective and does not have the gastrointestinal side effects associated with aspirin use.
Clinical Trials
Terutroban was investigated in a large-scale clinical trial called the PERFORM Study. However, the study was terminated early because Terutroban was not found to be superior to aspirin in preventing recurrent stroke or cardiovascular events.
Related Terms
- Thromboxane A2
- Ischemic stroke
- Cardiovascular disease
- Platelet aggregation
- Vasoconstriction
- Aspirin
- PERFORM Study
External links
- Medical encyclopedia article on Terutroban
- Wikipedia's article - Terutroban
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski